



MEN

FIRST CANCER SITE  
**NON-HODGKIN LYMPHOMA**

**NON-HODGKIN LYMPHOMA  
POOL AIRTUM 1976-2010, MEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**LINFOMA NON-HODGKIN  
POOL AIRTUM 1976-2010, UOMINI:**

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	26591		29800		29800		26591		19817		8724		3093		26591	29800
Person-years ▶	111563		116235		4672		18984		52881		27698		12001		111563	116235
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND NON-HODGKIN LYMPHOMA	1991	1.13	2333	1.27	342	4.50	293	0.98	919	1.10	535	1.21	244	1.25	2.00	4.21
HEAD AND NECK	91	1.18	107	1.33	16	4.73	12	0.89	49	1.33	20	1.07	10	1.27	0.13	0.23
ORAL CAVITY	21	1.14	24	1.25	3	3.80	1	0.32	10	1.14	7	1.55	3	1.54	0.02	0.04
PHARYNX	15	0.89	19	1.08	4	5.56	5	1.72	5	0.62	3	0.73	2	1.12	-0.02	0.01
LARYNX	55	1.32	64	1.47	9	4.80	6	0.81	34	1.70	10	1.00	5	1.20	0.12	0.18
OESOPHAGUS	13	0.67	16	0.79	3	3.52	2	0.59	3	0.32	5	1.05	3	1.47	-0.06	-0.04
STOMACH	116	1.10	122	1.10	6	1.23	25	1.33	49	0.97	35	1.36	7	0.65	0.09	0.10
COLON RECTUM	236	0.95	308	1.19	72	6.84	27	0.65	102	0.88	74	1.19	33	1.19	-0.10	0.43
COLON	176	1.04	233	1.32	57	7.95	17	0.60	78	0.98	55	1.28	26	1.34	0.05	0.48
RECTUM	60	0.78	75	0.93	15	4.47	10	0.76	24	0.66	19	0.98	7	0.83	-0.16	-0.05
LIVER	105	1.44	115	1.51	10	3.18	22	1.77	38	1.10	33	1.83	12	1.51	0.29	0.34
GALLBLADDER	16	0.85	18	0.91	2	2.39	3	0.93	10	1.12	2	0.42	1	0.49	-0.03	-0.02
PANCREAS	43	0.88	45	0.88	2	0.95	4	0.49	17	0.74	14	1.14	8	1.46	-0.05	-0.05
LUNG	403	1.29	469	1.43	66	4.74	60	1.10	186	1.25	109	1.42	48	1.46	0.80	1.22
SKIN MELANOMA	50	1.80	53	1.83	3	2.77	3	0.68	26	2.03	15	2.07	6	1.78	0.20	0.21
MESOTHELIOMA	14	1.43	16	1.57	2	5.05	2	1.26	6	1.32	4	1.60	2	1.74	0.04	0.05
KAPOSI SARCOMA	22	5.52	29	6.96	7	39.41	6	8.66	10	5.28	2	2.05	4	9.40	0.16	0.21
SOFT TISSUE	16	2.43	17	2.47	1	3.61	3	2.73	6	1.95	7	4.20	0	0.00	0.08	0.09
BONE	2	1.14	3	1.63	1	12.88	0	0.00	1	1.19	1	2.34	0	0.00	0.00	0.01
BREAST	5	1.28	6	1.47	1	6.02	0	0.00	1	0.54	2	2.04	2	4.61	0.01	0.02
PROSTATE	335	0.94	386	1.04	51	3.51	38	0.66	162	0.98	89	0.97	46	1.10	-0.18	0.14
TESTIS	11	2.83	12	2.98	1	6.64	1	1.60	7	3.88	2	2.01	1	2.19	0.06	0.07
KIDNEY AND RENAL PELVIS	79	1.37	109	1.81	30	12.54	33	3.44	22	0.81	16	1.09	8	1.22	0.19	0.42
BLADDER AND URINARY TRACT	235	1.18	274	1.32	39	4.48	21	0.62	126	1.34	57	1.15	31	1.44	0.32	0.57
URINARY BLADDER	229	1.20	266	1.34	37	4.45	21	0.64	123	1.37	55	1.16	30	1.45	0.34	0.58
URINARY TRACT	6	0.69	8	0.89	2	5.28	0	0.00	3	0.73	2	0.93	1	1.06	-0.02	-0.01
BRAIN AND CENTRAL NERVOUS SYSTEM	22	1.02	23	1.02	1	1.09	4	1.09	13	1.27	3	0.56	2	0.85	0.00	0.00
THYROID	13	1.36	14	1.41	1	2.71	4	2.63	6	1.36	3	1.21	0	0.00	0.03	0.03
HODGKIN LYMPHOMA	19	4.31	28	6.09	9	48.15	1	1.32	6	2.88	9	8.25	3	6.23	0.13	0.20
NON-HODGKIN LYMPHOMA	10	0.19	13	0.24	3	1.34	2	0.22	2	0.08	2	0.15	4	0.68	-0.39	-0.36
MYELOMA	9	0.38	9	0.37	0	0.00	1	0.25	3	0.27	4	0.68	1	0.39	-0.13	-0.13
LEUKAEMIAS	53	1.29	59	1.37	6	3.28	11	1.54	28	1.44	9	0.88	5	1.14	0.11	0.14
LYMPHOID LEUKAEMIAS	12	0.61	17	0.82	5	5.65	3	0.87	5	0.53	3	0.62	1	0.48	-0.07	-0.03
MYELOID LEUKAEMIAS	38	2.04	39	2.00	1	1.23	8	2.52	21	2.40	6	1.29	3	1.47	0.17	0.17
OTHER LEUKAEMIAS	3	1.10	3	1.04	0	0.00	0	0.00	2	1.51	0	0.00	1	3.79	0.00	0.00
OTHER AND ILL DEFINED SITES	83	0.89	95	0.98	12	2.94	10	0.63	42	0.96	20	0.86	11	1.07	-0.09	-0.02

■ Decrease/Difetto    ○ Observed cases    ■ SIR Standardized Incidence Ratio    ■ EAR Excess Absolute Risk  
■ Increase/Eccesso    ○ Casi osservati    ■ Rapporto standardizzato di incidenza    ■ Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE  
**NON-HODGKIN  
LYMPHOMA**

**NON-HODGKIN LYMPHOMA  
POOL AIRTUM 1976-2010, WOMEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**LINFOMA NON-HODGKIN  
POOL AIRTUM 1976-2010, DONNE:**

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	24563		27623		27623		24563		18491		8737		3337		24563	27623
Person-years ▶	110539		114869		4329		17530		51153		28749		13107		110539	114869
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND NON-HODGKIN LYMPHOMA	1219	1.12	1416	1.25	197	4.53	168	0.99	527	1.06	347	1.20	177	1.28	1.14	2.43
HEAD AND NECK	27	1.85	30	1.98	3	5.26	3	1.33	13	1.96	6	1.56	5	2.70	0.11	0.13
ORAL CAVITY	16	2.06	18	2.23	2	6.57	2	1.69	8	2.29	3	1.44	3	2.95	0.07	0.09
PHARYNX	4	1.23	5	1.48	1	7.94	0	0.00	2	1.34	1	1.18	1	2.48	0.01	0.01
LARYNX	7	1.97	7	1.90	0	0.00	1	1.79	3	1.84	2	2.16	1	2.30	0.03	0.03
OESOPHAGUS	5	0.93	8	1.43	3	13.53	2	2.38	2	0.82	0	0.00	1	1.47	0.00	0.02
STOMACH	58	0.92	63	0.96	5	1.80	5	0.49	31	1.08	15	0.91	7	0.93	-0.05	-0.02
COLON RECTUM	187	1.09	226	1.26	39	5.61	30	1.12	81	1.04	54	1.18	22	1.01	0.14	0.41
COLON	141	1.14	168	1.31	27	5.43	21	1.10	61	1.10	41	1.25	18	1.14	0.16	0.34
RECTUM	46	0.95	58	1.15	12	6.07	9	1.18	20	0.91	13	1.02	4	0.67	-0.02	0.07
LIVER	67	2.26	79	2.56	12	9.79	8	1.71	28	2.08	21	2.69	10	2.70	0.34	0.42
GALLBLADDER	16	0.69	17	0.70	1	1.01	3	0.80	3	0.28	9	1.49	1	0.35	-0.06	-0.06
PANCREAS	52	1.17	54	1.17	2	1.12	5	0.74	19	0.96	16	1.34	12	2.04	0.07	0.07
LUNG	94	1.31	108	1.45	14	5.06	12	1.11	33	1.02	33	1.71	16	1.69	0.20	0.29
SKIN MELANOMA	34	1.56	36	1.59	2	2.48	4	1.23	17	1.73	10	1.70	3	1.05	0.11	0.12
MESOTHELIOMA	6	1.94	7	2.18	1	8.68	1	2.18	3	2.17	1	1.20	1	2.39	0.03	0.03
KAPOSI SARCOMA	7	4.76	11	7.18	4	64.28	4	17.17	3	4.52	0	0.00	0	0.00	0.05	0.08
SOFT TISSUE	9	1.89	9	1.82	0	0.00	0	0.00	4	1.85	3	2.38	2	3.30	0.04	0.04
BONE	1	0.78	1	0.75	0	0.00	0	0.00	0	0.00	0	0.00	1	6.58	0.00	0.00
BREAST	300	1.02	352	1.15	52	4.60	37	0.81	127	0.94	82	1.05	54	1.46	0.05	0.40
CERVIX UTERI	12	0.79	14	0.88	2	3.14	2	0.79	5	0.70	2	0.52	3	1.77	-0.03	-0.02
CORPUS UTERI	46	0.87	51	0.93	5	2.43	5	0.60	22	0.91	15	1.09	4	0.62	-0.06	-0.03
OVARY	29	0.81	30	0.81	1	0.70	3	0.53	12	0.73	8	0.86	6	1.39	-0.06	-0.06
KIDNEY AND RENAL PELVIS	40	1.46	56	1.96	16	15.17	14	3.36	13	1.05	8	1.09	5	1.40	0.11	0.24
BLADDER AND URINARY TRACT	51	1.21	56	1.28	5	2.94	9	1.38	25	1.32	14	1.25	3	0.56	0.08	0.11
URINARY BLADDER	50	1.28	54	1.33	4	2.53	9	1.48	25	1.42	13	1.25	3	0.60	0.10	0.12
URINARY TRACT	1	0.34	2	0.65	1	8.29	0	0.00	0	0.00	1	1.26	0	0.00	-0.02	-0.01
BRAIN AND CENTRAL NERVOUS SYSTEM	17	1.03	18	1.05	1	1.53	4	1.55	5	0.66	6	1.38	2	0.97	0.00	0.01
THYROID	40	1.78	47	2.02	7	8.89	7	2.12	17	1.68	8	1.33	8	2.68	0.16	0.21
HODGKIN LYMPHOMA	8	2.66	11	3.51	3	24.70	1	2.05	2	1.43	2	2.58	3	8.68	0.05	0.07
NON-HODGKIN LYMPHOMA	18	0.42	19	0.43	1	0.59	5	0.76	7	0.36	3	0.27	3	0.56	-0.22	-0.22
MYELOMA	7	0.36	8	0.40	1	1.27	1	0.33	5	0.57	1	0.20	0	0.00	-0.11	-0.11
LEUKAEMIAS	30	1.10	32	1.13	2	1.76	1	0.23	14	1.13	13	1.81	2	0.60	0.02	0.03
LYMPHOID LEUKAEMIAS	1	0.08	3	0.24	2	3.92	0	0.00	0	0.00	0	0.00	1	0.71	-0.10	-0.08
MYELOID LEUKAEMIAS	29	2.22	29	2.13	0	0.00	1	0.49	14	2.37	13	3.74	1	0.60	0.14	0.13
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
OTHER AND ILL DEFINED SITES	76	0.95	92	1.10	16	4.82	7	0.56	43	1.20	20	0.94	6	0.58	-0.04	0.08

Decrease/Difetto  
Increase/Eccesso

Observed cases  
Casi osservati

SIR Standardized Incidence Ratio  
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk  
Eccesso assoluto di rischio